Applying trained immunity therapy in NASH-HCC patients may initially encounter greater resistance, as trained monocytes could be rapidly deactivated by elevated IL-10 and fatty acids in NASH livers, while trained neutrophils might revert under NASH-associated cytokines. Here, IL10 is linked to hepatocellular carcinoma.